The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pretreatment characteristics and early indicators of long-term efficacy of cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (rmSCCHN).
Ulrich Keilholz
Consultant or Advisory Role - Merck
Honoraria - Merck Serono
Research Funding - Merck Serono
Maren Knoedler
Honoraria - Merck Serono
Ines Redlich
No relevant relationships to disclose
Thomas Christoph Gauler
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono